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1. General introduction 
 
1.1. The importance of glucose: two methods of transport 
 
Glucose is the major energy source for all living organisms and it is a structural 
precursor for the biosynthesis of proteins, lipids, and nucleic acids. It provides energy in 
the form of ATP through glycolysis and the citric acid cycle as well as reducing power in 
the form of NADPH trough the pentose phosphate shunt. It is also used in the synthesis of 
glycerol for triglyceride production and provides intermediates for the synthesis of 
nonessential aminoacids. Moreover, in lactating animals, a major portion of blood glucose 
is used for the synthesis of lactose, the major milk carbohydrate, in the mammary gland. 
Glucose is a hydrophilic molecule and cannot cross the plasma membrane freely, 
therefore a carrier system is required to promote its transport. The plasma membranes of 
all mammalian cells possess one or more transport systems to allow glucose movement 
either into or out of the cells. 
Two kinds of transport can be distinguished: the facilitative one, and the sodium-
dependent one. The first is a passive transport, driven by the downward glucose 
concentration gradient across the plasma membrane and is the method of transport 
widespread in most of the cells of the organism. The other is used only in the epithelial cell 
brush border of the small intestine and in the kidney proximal convoluted tubules, where 
glucose is absorbed or reabsorbed against its electrochemical gradient by a secondary 
active transport mechanism; for the operation of this transport is required the sodium 
concentration gradient established by Na+/K+/ATP pumps.  
This two kinds of transport processes are mediated by two distinct families of 
structurally related glucose transporters: the passive, facilitative transport process is 
mediated by the family of facilitative glucose transporters (gene symbol SLC2A, protein 
symbol GLUT); the sodium-dependent glucose transport process is mediated by the family 
of Na+/glucose cotransporters (gene symbol SLC5A, protein symbol SGLT). Thus far, at 
least six members of this second family have been reported, but only SGLT1 and SGLT2 
have been well characterized (Zhao & Keating, 2007). 
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1.2. GLUTs: structure and localization 
 
Thirteen members of facilitative glucose transporters (GLUTs) have been identified 
so far: GLUT 1-12 and HMIT (H+/myoinositol transporter). Each of the glucose 
transporter proteins possesses different affinities for glucose and other hexoses, such as 
fructose. Moreover, each isoform has a tissuespecific distribution and more than one 
isoform may be expressed in the same tissue at either the same or different times. (Table 
1). 
 
Table 1. Summary of the properties of facilitative glucose 
transporter (Zhao & Keating, 2007). 
 
Protein Major isform (aa count) Km (mM) 
Major sites of 
expression Proposed function 
GLUT-1 492 3-7 
Ubiquitous distribution 
in tissues and culture 
cells 
Basal glucose uptake; 
transport across blood 
tissue barriers 
GLUT-2 524 17 Liver, islets, kidney, 
small intestine 
High-capacity low-
affinity transport 
GLUT-3 496 1.4 Brain and nerves cells Neuronal transport 
GLUT-4 509 6.6 Muscle, fat, heart 
Insulin-regulated 
transport in muscle and 
fat 
GLUT-5 501  Intestine, kidney, testis Transport of fructose 
GLUT-6 507 ? Spleen, leukocytes, brain 
 
GLUT-7 524 0.3 Small intestine, colon, testis Transport of fructose 
GLUT-8 477 2 Testis, blastocyst, brain, 
muscle, adipocytes  
GLUT-9 511/540 ? Liver, kidney 
 
GLUT-10 541 0.3 Liver, pancreas 
 
GLUT-11 496 ? Heart, muscle Muscle-specific; fructose transporter 
GLUT-12 617 ? Heart, prostate, 
mammary gland  
HMIT 618/629 ? Brain H+/myo-inositol co-transporter 
 
 
These differences reveal that each transporter isoform plays a specific role in glucose 
uptake in various tissues and in glucose homeostasis. 
Based on the phylogenetic analysis of sequence similarity, the GLUT family of sugar 
transporters are divided into three classes: 
Class I includes GLUT-1-GLUT-4 which have been extensively characterized. 
Class II comprises the fructose transporters GLUT-5 and three recently described 
proteins, GLUT-7, GLUT-9 and GLUT-11. Structurally, the four transporters of this class 
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do not have the key tryptophan residue, which was instead shown to be important in class I 
GLUTs for their binding to ligands such as cytochalasin B and forskolin at the level of 
transmembrane helix 10 (TM10). 
Class III comprises five newly described proteins, GLUT-6, GLUT-8, GLUT-10, 
GLUT-12 and HMIT. 
Alignments of the amino acid sequences show that there is 39-65% identity between 
the well-characterized human GLUT 1-5, and at least 28% identity between GLUT-1 and 
each of the new GLUTs (Macheda et al., 2005). 
The tertiary structure of the GLUTs present 12 hydrophobic α-helical transmembrane 
domains (TMs), crossing the cell membrane. The NH2- and the COOH-termini of the 
protein are both located on the cytoplasmic side of the membrane and there is a large 
intracellular loop between TM6 and TM7 (Fig. 1). 
 
Fig. 1. Models of the orientation of facilitative glucose transporter 
proteins in the cell membrane (Macheda et al., 2005). 
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Sequence comparisons of all the 13 family members show that there is a high degree 
of homology across the transmembrane helices, while the NH2- and COOH-termini and 
loop sequences are variable. In addition, there are 18 conserved glycine residues, 11 of 
them are adjacent to at least one other conserved aminoacid. 
The presence of a common motif suggest that this family may have originated from a 
common ancestral gene (Zhao & Keating, 2007). 
The class I and II members of the family have a large predicted extracellular loop 
between TM1 and TM2, which contains an N-linked glycosylation site. 
Glycosylation of GLUT-1 at this site was shown to increase the efficiency of the 
glucose transport process (Macheda et al., 2005). 
 
1.3. Characteristics of GLUT-1 and its interaction with D-glucose 
 
The deduced protein sequence of GLUT-1 is composed of 492 amino acid in human, 
bovine, rat and mouse, with a molecular weight of approximately 54 kDa. It is the most 
conserved isoform and exhibits approximately 74-98% sequence identity among these 
species. 
The last 24 amino acids at the C-terminus of GLUT-1 were shown to be unnecessary 
for the transport activity; whereas there is now a consolidated opinion that the N- and O-
glycosylation of GLUT-1 is essential for its transporter activity (Zhao & Keating, 2007). 
GLUT-1 isoform is also known as the erythrocyte, brain, or Hep-G2-Type glucose 
transporter and comprises 3-5% of the erythrocyte total membrane protein. In particular, it 
is expressed at high levels in endothelial and epithelial-like barriers of the brain, eye, 
peripheral nerve, placenta and lactating mammary gland. It was shown to play a critical 
role in development of the vertebrate brain. 
GLUT-1 protein also acts in a cooperative manner with other isoforms and this is 
confirmed by the interaction between GLUT-1 and GLUT-4 in insulin sensitive tissues, 
such as fat and muscle, where the GLUT-1 protein is localized in the plasma membrane, 
and the tissue-specific GLUT-4 is distributed in an intercellular compartment. 
Regarding the interaction of D-glucose with the GLUT protein, the main residues 
involved seem to be Gln168 in TM5, Gly388 in TM10, Gln175 and Ile171 in TM5, Phe383 
in TM10 and Gln415 in TM11, as shown in Fig. 2. There is also a water-mediated H-bond 
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between Gln414 and D-glucose. These interaction were determinated by using an 
homology models of human GLUT-1 (Tuccinardi et al., 2013). 
 
 
Fig. 2. Interaction between D-glucose and the functional residues of GLUT. 
 
 
1.4. Overexpression of GLUT-1 in cancer cells 
 
Malignant cells display an accelerated metabolism, high glucose requirements, and 
an increased glucose uptake in order to meet their augmented energy requirements for 
rapid growth and invasiveness. A high-rate glycolysis is a fundamental property of solid 
tumors and is associated with an overexpression of glucose transporters and glycolytic 
enzymes. The main GLUT transporter overexpressed in cancer cells is GLUT-1, which is a 
high affinity glucose transporter; its overexpression has been widely observed in many 
cancer tissues and cells, including hepatic, pancreatic, breast, esophageal, brain, renal, 
lung, cutaneous, colorectal, endometrial, ovarian and cervical carcinoma(Macheda et al., 
2005). 
It is clear that up-regulation of GLUT-1 expression occurs in the process of 
malignant transformation and this increased expression may be a fundamental part of the 
neoplastic progression. However, an alternate interpretation of the data is that increased 
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GLUT-1 protein levels in transformed cells may be an indirect effect. In fact, according to 
this second hypothesis, increased glucose consumption could result in decreased 
intracellular glucose concentration, thus stimulating GLUT-1, which would then be 
secondary to the lower intracellular glucose levels. Whether it is a cause or an effect, the 
fact remains that the increased GLUT levels are correlated with advanced tumor grade, 
increased proliferation, and decreased survival (Wood et al., 2008). Furthermore several 
studies have demonstrated a link between GLUT-1 expression and chemoresistance, tumor 
aggressiveness and poor survival (Ulanovskaya et al., 2011), and in another study it was 
hypothesized that the overexpression of glucose transporters prevents apoptosis, promotes 
cancer cell survival, and confers drug resistance (Cao et al., 2007). 
This metabolic alteration that occurs in cancer cells is known as the “Warburg effect” 
(Fig. 3) and it is characterized by the fact that glycolysis remains active even under aerobic 
conditions: in fact hypoxic cancer cells are not able to produce energy through the 
oxidative phosphorylation (OXPHOS) because of the low concentration of oxygen. 
Therefore, these cells display a shift from OXPHOS to glycolysis to generate ATP and 
anabolites. During the glycolytic process glucose undergoes several chemical 
transformations into smaller structures with the production of energy in the form of ATP 
Fig. 3. The “Warburg effect”. 
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molecules. The end product of glycolysis is pyruvate. Under hypoxic conditions pyruvate 
cannot take part of the citric acid cycle in mitochondria, and is therefore transformed into 
lactate by lactate dehydrogenase (LDH). 
In healthy cells, the glycolytic process is coupled to the mitochondrial OXPHOS, 
which allows the production of ~36 ATP molecules per glucose molecule, and pyruvate is 
eventually transformed into CO2. Tumor cells living in hypoxic conditions cannot carry out 
mitochondrial OXPHOS and, hence, pyruvate undergoes a final LDH-promoted reduction 
to lactic acid which is then extruded out of the cells by specific transporters, thus 
contributing to the generation of extracellular tumor acidosis. 
The “Warburg effect” has been attributed to increased expression of factors such as 
hypoxia-inducible factor 1α (HIF-1α) and 5’-AMP-activated protein kinase (AMPK) that 
up-regulate genes involved in glycolysis and down-regulate genes involved in oxidative 
metabolism of pyruvate. (Fig. 4). 
 
 
 
Fig. 4. Involvement of HIF-1α and AMPK (red circles) in the regulation 
of expression of several glycolytic effectors (Semenza, 2010). 
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In the light of these considerations, it appears clear that inhibition of GLUT-1 
functionality may be a promising therapeutic strategy for sensitization of cancer cells to 
chemotherapeutic agents and for direct targeting of cancer cells. Therefore, the purpose of 
this thesis is to synthesize molecules that efficiently inhibit GLUT-1 transporters and 
promote an antiproliferative effect in cancer cells. 
 
1.5. GLUT interacting molecules: background 
 
1.5.1. Flavonoids 
 
Flavonoids are polyphenols that are widely distributed in foods, especially fruits and 
vegetables. They are comprised of about 4000 compounds which occur naturally in both 
flowering and nonflowering plants. Nutritive function of flavonoids are unknown, but it 
has been amply demonstratet that they exert inhibitory effects on glucose transporters. 
The inhibitory potency of hydroxylated flavonoids depends on the pH of the 
medium: the apparent affinity is maximal at low pH where the molecule is in the 
undissociated neutral form. In fact, flavonoids possessing hydroxyl groups are weak acids 
which could be deprotonated at high pH-values. The inhibitory activity in glucose efflux of 
planar flavonoids considerably increases with the number of hydroxyl groups present in the 
molecule (Martin et al., 2003). For example one of these hydroxylated flavonoids is 
naringenin (Fig. 5), a grapefruit flavanone, known for its ability to bind the estrogen 
receptor β with high affinity. It was reported that naringenin inhibits also insulin-
stimulated glucose uptake in proliferating and growth-arrested MCF-7 breast cancer cells 
by inhibition of GLUT-4 transporter. In fact, at a concentration of 100 µM, naringenin 
Fig. 5. Naringenin. 
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proved to inhibit glucose uptake by ~ 50 % and cell proliferation by ~ 20 % (Harmon & 
Patel, 2004). 
Another polyhydroxylated flavonoid is quercetin (Fig. 6), a food component with an 
excellent pharmacology safety profile. Quercetin is a commonly ingested flavonoid, and 
20-100 mg daily is ingested by dietary intake. Peak plasma concentrations of flavonoids 
such as quercetin do not exceed 1-2 µM after ingestion, but intestinal luminal 
concentrations are believed to be ~10-fold higher (11-14 µM) (Kwon et al., 2007). Based 
on these high intraluminal concentrations, quercetin shows promise as new pharmacologic 
agents in the obesity epidemic because of its capacity to inhibit the sugar transporter 
GLUT-2, the isoform mostly present in the intestine.  
 
 
 
Fig. 6.  Quercetin. 
 
 
Other similar flavonoids, such as myricetin (Fig. 7), fisetin (Fig. 8) and isoquercetin 
(Fig. 9), the glucoside analogue of quercetin, proved to inhibit GLUT-2, just like quercetin 
itself does. 
 
 
 
 Fig. 7. Myricetin. Fig. 8. Fisetin. 
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Fig. 9. Isoquercetin (R=β-D-glu). 
 
 
Another natural flavonoid, Silybin (SIL; Fig. 10), also known as silibinin, is the 
major active component of silymarin, an extract of the blessed milk thistle Silybum 
marianum Gaertnei, and consists of the diastereomers silybin A and B (Davis-Searles et 
SIL A 
SIL B 
DHS 
Fig. 10. Diastereomers of Silybin and Dehydrosilybin. 
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al., 2005). Silybum marianum has been used in the treatment of liver diseases for two 
millennia. Several clinical trials have highlighted the beneficial effects of SIL for non-
alcoholic fatty liver diseases, chronic hepatitis C infection, and insulin resistance 
associated with chronic hepatic diseases. In addition there is considerable data showing 
strong inhibitory effects of SIL on the proliferation and survival of different cancer cells in 
vitro and in vivo, including clinical trials that assess its effectiveness in patients. 
2,3-Dehydrosilybin (DHS; Fig. 10), an oxidized form of SIL, occurs naturally in the 
fruit of the Eurasian spotted milk thistle and is reported to possess stronger anti-oxidant 
and anti-cancer effects than SIL. 
Most of the biological effects of SIL have been attributed to its anti-oxidant capacity. 
However, recent publications identified SIL as an inhibitor of insulin-mediate glucose 
uptake, but the exact mechanism of this inhibitory effect was not completely resolved. 
A recent study (Zhan et al., 2011) shows that SIL and DHS inhibit cellular glucose 
uptake by a direct interaction with GLUT-4 rather than an interference with insulin 
signalling or GLUT-4 translocation. Moreover this study confirms that SIL and DHS share 
the same binding site as glucose and that they affect glucose uptake by directly reducing 
glucose binding to GLUT-4.  
Both SIL and DHS inhibit glucose uptake in a competitive manner with Ki values of 
60 and 114 µM, respectively (Zhan et al., 2011). The inhibitory capacity of SIL and DHS 
is therefore most likely not restricted to GLUT-4 but includes other GLUT isoforms. While 
SIL shows higher affinity towards GLUT-4, which is demonstrated by its lower Ki value, 
DHS is a much stronger inhibitor in cells that predominantly express GLUT-2 or GLUT-1. 
Genistein (Fig. 11), an isoflavone which is present in large amounts in soya-bean 
extract, inhibits glucose transport directly by interacting with GLUT-1 in human 
erythrocytes (Ki = 12µM) (Afzal et al., 2002). 
 
 
 
 
Fig. 11. Genistein. 
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However, the antitumor effects of flavonoids cannot be entirely associated with their 
inhibition of glucose uptake, as at least a part of this action may also be due to their well-
known antioxidant or estrogen receptor beta binding properties (Granchi & Minutolo, 
2012). 
 
1.5.2. Phloretin, Forskolin, Cytochalasin B 
 
Phloretin (Fig. 12), a dihydrochalcone found in apple tree leaves, acts as a 
competitive inhibitor of GLUT-1 and is known for its ability to retard tumor growth in 
vitro and in vivo. It was demonstrated that phloretin sensitizes cancer cells to 
chemotherapeutic agents such as Daunorubicin in colon cancer, non-small-cell-lung 
cancer, and renal carcinoma cells in hypoxia (Granchi & Minutolo, 2012). 
 
Fig. 12. Phloretin. 
 
In a study phloretin did not exhibit any cell killing effect at concentrations lower than 
50 µM; moreover higher concentrations of phloretin (1 mM) completely blocked glucose 
uptake and inhibited cell growth in both drug sensitive and drug-resistant cancer cells (Cao 
et al., 2007). Moreover early investigation showed that the hydroxyl groups at position 2, 4 
and 6 are important for the inhibitory action of phloretin. In fact 2,6-dimethoxy-phloretin is 
completely inactive. This suggested the formation of an additional ring (intramolecular 
chelate or H-bond) in phloretin which forces the molecule to adopt a more planar and less 
flexible structure (Martin et al., 2003). 
Another GLUT inhibitor is Forskolin (Fig. 13), a labdane diterpene produced by the 
Indian Coleus plant, which shows the same property of phloretin. Forskolin, as well as 
phloretin, binds an extracellular binding site situated in the extracellular opening of the 
GLUT-1, and an intracellular binding site, localized in a cavity near the intracellular 
opening of the channel (Salas-Burgos et al., 2004). 
 
 15 
 
 
Fig. 13. Forskolin. 
 
 
Cytochalasin B (Fig.14) is a fungal toxin, that inhibits the D-glucose uptake in 
erythrocytes, whose structure inspired the discovery of other new derivatives, displaying 
inhibitory properties on GLUT-1 (Granchi & Minutolo, 2012). 
 
 
Fig. 14. Cytochalasin B. 
 
These compounds proved to block the formation of glycolytic metabolites in cancer 
cells and to suppress ATP synthesis when associated with the blockage of mitochondrial 
function by other agents. 
 
1.5.3. Methylxanthines 
 
Methyxanthines (Fig. 15) are a family of natural compounds with a vast variety of 
physiological effects, including inhibition of glucose transport. For example, theophylline 
(1,3-dimethylxanthine) relaxes smooth muscle, stimulates heart activity, activates the 
central nervous system and increases diuresis. Caffeine (1,3,7-trimethylxanthine) acts at 
the level of skeletal muscle, increasing the contractile response. On the other hand, the 
synthetic methylxantines pentoxifylline [1-(5-oxohexil)-theobromine] and isobutyl-
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methylxanthine are prescribed for the treatment of cardiovascular disorders. Pentoxifylline 
increases the erythrocyte deformability of damaged erythrocytes and reduces platelet 
aggregation, fibrinogen levels, adhesion to the endothelium and activation of leukocytes 
and the resulting endothelium damage. It also decreases blood viscosity, thus facilitating 
microcirculatory perfusion through improved blood flow.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15. Methylxanthines. 
 
 
Inhibition of glucose transport by some of these xanthines has been described in 
human erythrocytes and the evidence suggests that caffeine and theophylline interact 
directly with GLUT-1 and, in particular, that the synthetic 3-isobutyl-1-methylxanthine 
binds to the extracellular face of this transporter. The inhibitory mechanism of 
methylxanthine on GLUT-1 is, however, still unknown.  
Using a GLUT-inhibition assay based on cytochalasin B displacement (the amount of 
cytochalasin B that remains bound to erythrocyte membranes is measured as a function of 
increasing concentrations of methylxanthines), it was determined that pentoxyfylline is 
more potent than caffeine and theophylline and the Ki values of pentoxifylline, caffeine 
and theophylline were 0.64, 1.5 and 3.2 mM respectively (Ojeda et al., 2012). 
Theophylline Caffeine 
Pentoxifylline Isobutyl-methylxanthine 
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Moreover with this study it was demonstrated that the inhibitory effect on glucose 
transport is due to the direct interaction of methylxanthines with GLUT-1 and is not related 
to perturbation of other properties, such as membrane fluidity. Furthermore, there is a 
common binding site for methylxanthines at the external face of GLUT-1, which is 
different but located close to the glucose-binding site. 
 
1.5.4. Barbiturates  
 
Barbiturates, such as pentobarbital, thiobutabarbital and barbital inhibit hexose 
transport by directly interacting with GLUT-1 in cultured mammalian cells and in human 
red cells. A study has been conducted to demonstrate the hypothesis that barbiturates 
inhibit GLUT-1 function by interacting with the occupied and/or unoccupied GLUT-1 
transporter. This experiment involves the measurement of both unidirectional “zero trans” 
and equilibrium exchange fluxes of radiolabeled hexoses in the functionally well-
characterized GLUT-1 rich human erythrocytes system. Influx is measured under the 
conditions of initially zero concentration of sugar inside the erythrocyte (zero trans) and 
variable sugar concentration outside the cell; efflux is measured under the opposite 
conditions, namely, zero sugar concentration outside (zero trans) the erythrocyte and 
appreciable but variable sugar inside the cell. 
It was demonstrated that barbiturates are noncompetitive inhibitors of glucose 
translocation and preferentially inhibit the unoccupied form of the carrier (El-Barbary et 
al., 1996). 
 
1.5.5. Thiazolidinedione derivates 
 
The antitumor effect of 5-{4-[1-methyl]lcyclohexyl)methoxy]benzyl}thiazolidine-
2,4-dione, a thiazolidinendione peroxisome proliferator-activated receptor gamma (PPAR-
γ) agonist, was in part attributable to its ability to block glucose uptake independently of 
PPAR-γ (Wang et al., 2012). Thus, some PPAR-γ inactive thiazolidinedione analogues  
were developed to constitute a new class of GLUT inhibitors. The structure of one of the 
most promising compounds is reported in Fig. 16. The inhibitory effect of this compound 
is due to its capacity to bind the GLUT-1 channel at a binding-site distinct from that of 
glucose. Docking analysis indicates that the molecule interacts with the putative binding 
site through electrostatic and π-π stacking interactions in the central region of the channel 
(Tyr28, Arg126, Thr137, His160, Gln282).  
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Fig. 16. The best molecule found among the thiazolidinedione derivatives. 
 
 
1.5.6. Tricyclic antidepressants 
 
Tricyclic antidepressant amitriptyline, desipramine, nortriptyline and imipramine all 
inhibit the influx of glucose into erythrocytes with a concentration in the millimolar range. 
All four antidepressants also noncompetitively displace cytochalasin B by binding to 
GLUT-1 (Ki ranges from 0.56 to 1.43 millimolar) (Pinkofsky et al., 2000). 
The interaction of the tricyclic antidepressants with the erythrocyte glucose 
transporters was studied by using the cytochalasin B binding assays. The observed 
noncompetitive kinetics of cytochalasin B displacement suggest that tricyclic 
antidepressants interact directly with the transport protein. 
 
1.5.7. Antiestrogens 
 
The antiestrogens tamoxifen, cyclofenil and diethylstilbestrol (Fig. 17) are potent 
inhibitors of glucose transport in human red cells. However, in contrast to flavonoids, these 
antiestrogens demonstrate no pH-dependence in the inhibition of glucose transport (Martin 
et al., 2003). All these three substances have Ki values in the micromolar range regardless 
the pH of the medium. 
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Fig. 17. Antiestrogens that inhibit GLUT-1. 
 
Tamoxifen Cyclofenil 
Diethylstilbestrol 
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2. Introduction to the experimental section  
 
Bearing in mind that some molecules, belonging to the class of flavonoids, such as 
Myricetin, Quercetin and Genistein, are active not only on glucose transporters but also on 
oestrogen receptor β (ERβ), it was thought that probably other molecules, known to be 
good ligands of ERβ and which have high structural overlaps with flavonoids, may have 
good chances of displaying good inhibitory activities also on GLUT.  
Considering this hypothesis, some biaryl oxime ligands, which have been previously 
synthesized as potential ERβ ligands by the research team I have been working with during 
my thesis, were tested on GLUT-1 in cell-based assays to evaluate their inhibitory 
properties. These experiments were conducted by the research group of Xiaozhuo Chen at 
the Edison Biotechnology Institute of the Ohio University. Dr. Chen had previously 
discovered an efficient inhibitor of GLUT-1, compound WZB117 (Fig. 18), which was 
used as the reference inhibitor also in our assays. 
These studies proved that among the oxime derivatives tested (1-13; Fig. 19) are 
good inhibitors of GLUT-1, thus justifying the interest in the extension of this chemical 
class in my thesis project.  
 
 
 
Fig. 18. Structure of WZB117. 
 
 
In details, reference GLUT-1 inhibitor WZB117 inhibits cell growth in cancer cell 
lines, but it also demonstrated in vivo efficacy by inhibiting tumor growth in a nude mouse 
xenografts model. In fact, it was observed that daily intraperitoneal injection of WZB117 
at the concentration of 10 mg/kg resulted in a more than 70% reduction in the size of 
human lung cancer of A549 cell origin. In particular, cells were treated with compound 
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WZB117 for 24 or 48 hours. The inhibitory activity of compounds on glucose transport 
was analyzed by measuring the cell uptake of 2-deoxy-D-[3H]-glucose. Glucose uptake 
assays showed that WZB117 inhibits glucose transport in cancer cells in a dose-dependent 
manner. It also revealed that the inhibition of glucose transport induced by WZB117 
occurred within 1 minute after the assay started, suggesting that the inhibitory activity 
likely occurs via a direct and fast mechanism. Cell viability assay showed that WZB117 
inhibited cancer cell proliferation with an IC50 of approximately 10 µmol/L. Studies on the 
mechanism of action of WZB117 demonstrated that this compound inhibited glucose 
transport in human red blood cells (RBC), which express GLUT-1 as their exclusive 
glucose transporter. Furthermore, treatment of A549 cancer cells with WZB117 led to 
decreased levels of GLUT-1, intracellular ATP, and glycolytic enzymes (Liu et al., 2012). 
For these reasons, WZB117 constitutes a valid reference compound for our efforts 
devoted to the discovery of potential anticancer therapeutics targeting GLUT-1-mediated 
glucose transport and glucose metabolism. 
As regards the oxime derivatives generated at the University of Pisa (1-13, Fig 19), 
the biological assays described above proved that in most cases there is a substantial 
reduction (70-90%) of the glucose uptake by non-small cell lung carcinoma (NSCLC) 
H1299 cells at a 30 µM concentration. Moreover some of these compounds (3, 6, 11-13) 
displayed activities which were comparable to, or higher than, reference GLUT-1 
inhibitors, such as phloretin and WZB117 at the same 30 µM concentration (Fig. 20, upper 
graph) (Tuccinardi et al., 2013). 
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These compounds were then subjected to an antiproliferative assay against the same 
H1299 cancer cells. Aldoxime 6 and ketoximes with the aryl substituent in the para-
position (12 and 13), displayed the most interesting combined properties in terms of 
inhibition of glucose transport and of cell viability. (Fig. 20, lower graph). 
Furthermore, IC50 values were determined in these two assays the most promising 
molecules. Table 2 summarize the most significant IC50 data obtained for representative 
ketoxime 13 and those of reference inhibitors Phloretin and WZB117 for comparison. 
These data confirm that ketoxime 13 is more active than phloretin in inhibiting the 
glucose uptake by H1299 cells and this activity compares nicely to that of reference 
inhibitor WZB117. The antiproliferative assay showed that 13 is more potent than 
phloretin, although its activity is lower than that of WZB117. 
Finally the research group where I carried out my thesis started a computational 
analysis aimed at determining the way these compounds interact with GLUT-1.  
Unfortunately, for these purposes, there were no X-ray structures available of human 
GLUT-1. However, the recently deposited structure of XylE, an Escherichia coli 
homologue of GLUT-1-4, showed the best sequence similarity (29% of identities) with 
human GLUT-1. This transporter is also composed by 12 transmembrane helices with the 
amino and carboxy termini both located on the intracellular side. 
 
Fig. 19. Structures of oxime derivatives 1-13, which were screened for 
inhibition GLUT-1 and for antiproliferative effect in cancer cells. 
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Fig. 20. Inhibition % of glucose uptake (upper panel) and of cell viability after 
48 h (lower panel) in H1299 lung cancer cells by compounds 1-13 and by 
reference inhibitor WZB117 and Phloretin at a 30 µM concentration. in H1299 
lung cancer cells by compounds 1-13 and by reference inhibitor WZB117. 
 
Table 2. IC50 values. 
 
Compound IC50 value in glucose uptake (µM ± SD) 
IC50 value in cell viability 
(µM ± SD) 
13 10.6 ± 2.8 34.8 ± 5.8 
Phloretin 21.4 ± 5.1 54.0 ± 14.6 
WZB117 10.9 ± 3.6 20.4 ± 4.8 
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The sequence alignment of XylE was compared to several GLUT transporters and, 
on the basis of the resulting alignment, the GLUT-1 model was built. As shown in Fig. 21, 
the resulting model displays the presence of one large extracellular cavity (green), one 
pocket in the transmembrane domain, corresponding to the D-glucose binding site in the 
XylE X-ray structure (purple), and a third cavity in the intracellular region of the receptor 
(cyan). These studies produced strong support to the fact that the intracellular cavity is the 
one involved in the binding of reference ketoxime derivative 13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21. Analysis of the cavities of the newly developed hGLUT-1 model.  
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3. Experimental section 
 
As reported in the previous section, one of the most promising molecule active on 
glucose uptake inhibition was compound 13. On the basis of computational studies, 
conducted in our department by Tiziano Tuccinardi and Adriano Martinelli, it was seen 
that the functional groups of this type of ketoximes involved in the interaction with GLUT-
1 are: 
1. the hydrogen atom of the oxime OH group of the pseudo cycle C, which binds 
Glu146; 
2. the oxygen atom of the hydroxyl group of ring A, which accepts an H-bond from 
Arg153;  
3. the chlorine atom of ring B, which closely interact with Arg232 (Fig. 22). 
 
 
 
 
Fig. 22. Interaction between a generic ketoxime derivative and GLUT-1. 
 
A 
B C 
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Moreover, the planarity given by the pseudo cycle C seems to be important, because 
it allows the oxime and the hydroxy groups to reach the appropriate distance to bind 
Arg153 and Glu146, thus mimicking the flavonoid scaffold. The methyl substituent of the 
ketoxime group is also important for the activity because it is surrounded by a hydrophobic 
environment, such as that produced by the aromatic side chain of Phe213. Phe460 seems to 
give a π-π stacking interaction with ring A. 
In the light of these results, the project of my thesis work aims at synthesizing new 
molecules belonging to the same ketoxime class, whose structures are based on the 
scaffold of reference compounds 12 and 13, which proved to efficiently inhibit GLUT-1. 
In particular, during the period spent in the research lab I have obtained eight novel 
molecules (14-21; Fig. 23). In all cases the structural modifications leading to the new 
molecules involved the various substitutions introduced in aromatic ring A, since this 
portion of the molecule resulted to be more suitable to variation in accordance to the 
above-mentioned model. In details my compounds preserved the presence of hydrogen-
bond acceptor groups, such as methoxy, trifluoromethoxy or cyano, either in the meta or in 
the para position of the aryl ring (compounds 14-19). Moreover, I have replaced the m-F 
atom of compound 12 with either a m-Cl (20) or a m-CH3 (21) group. 
A dedicated molecular modelling analysis of a representative example of my 
compounds (ketoxime 14) in our model of the GLUT-1 transporter (Fig. 24), demonstrated 
that this compound nicely fits in the intracellular cavity of the protein, where it maintains 
all the crucial interactions previously found with the reference inhibitors. 
The synthetic strategy with which I have obtained these compounds was similar to 
the strategy used by the research group where this thesis was carried out to synthesize 
salicylaldoximes, with the purpose of obtaining ER-β ligands (Minutolo et al., 2009). 
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Fig. 23. Structures of compounds synthesized during my thesis work. 
 
14                                                                    15 
16                                                                    17 
18                                                                    19 
20                                                                    21 
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Fig. 24. Docking of the interaction between a representative oxime 
that I have synthesized (Compound 14, Fig. 24) and GLUT-1. 
 
This synthetic pathway consisted to start from a key intermediate constituting the 
substitued aromatic ring B (which is the common starting molecule to obtain all final 
compounds), which is submitted to a “Suzuki-type” Pd-catalyzed a cross-coupling reaction 
with different boronic acids (A) (Scheme 1). 
 
 
Scheme 1. Cross coupling reaction. 
Na2CO3 (aq) 
Pd(OAc)2 
P(Ph)3 
EtOH, Toluene 
100 °C, 16h 
B A 
22 23 a-h 24 a-h 
a: p-OCF3                             b: m-OCF3 
c: p-OCH3                            d: m-OCH3 
e: p-CN                      f: m-CN 
g: p-OCH3, m-Cl        h: p-OCH3, m-CH3 
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The final step of this synthetic procedure is the creation of the oxime, which forms a 
pseudo cycle through a hydrogen bond with the phenolic hydroxyl of the B ring. The 
oxime can be obtained by a condensation of hydroxylamine to the carbonylic group of B 
ring (Scheme 2). 
 
 
 
 
Scheme 2. Creation of the oxime. 
 
 
To obtain the properly substituted B ring of key intermediate 22 the synthetic 
pathway shown in the Scheme 3 was followed. 
 
 
 
 
 
 
 
 
 
 
 
NH2OH HCl 
EtOH,  
50 °C, 16h 
B 
A A 
B 
24 a-h 14-21 
14: p-OCF3                            15: m-OCF3 
16: p-OCH3                           17: m-OCH3 
18: p-CN                      19: m-CN 
20: p-OCH3, m-Cl         21: p-OCH3, m-CH3 
a: p-OCF3                             b: m-OCF3 
c: p-OCH3                            d: m-OCH3 
e: p-CN                       f: m-CN 
g: p-OCH3, m-Cl         h: p-OCH3, m-CH3 
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(a) NaH, THF, Diethylcarbamyl-chloride, RT, 3 h 
(b) LDA, THF, C2Cl6, 0 °C to -78 °C, then RT, 1.5 h 
(c) NaOH, EtOH, 100 °C, 12 h 
(d) Dioxane, NaOH, cat TBAHS, Acetylchloride, RT, 1.5 h 
(e) AlCl3, 130 °C, 3 h 
 
Scheme 3. Synthetic pathway to obtain key intermediate 22. 
 
 
In detail, commercial product 3-bromophenol was deprotonated with NaH in THF 
(Minutolo et al., 2009). The resulting phenate nucleophile reacted with diethylcarbamoyl 
chloride to obtain compound 26 by a classic acylation (Scheme 4): 
 
 
 
Scheme 4. Phenol carbamoylation. 
25 25a 26 
25 26 27 
28 29 22 
(a) (b) 
(c) 
(d) (e) 
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This step is required for the next metalation reaction: in fact the carbamoyl group is 
not only compatible with the subsequent reaction, but it also activates the ortho position of 
the aromatic ring for the lithiation. 
The second step of the synthesis is a regioselective ortho-lithiation, which allows the 
insertion of a chlorine atom in the aromatic ring (Scheme 5). This reaction consists in the 
site-selective replacement of an aryl hydrogen atom with lithium for the purpose of further 
functionalization (Sibi & Snieckus, 1983). The regioselectivity of this reaction is due to the 
effect of the carbamoyl group, that directs the metalation to the arylic site closest to the 
heteroatom of the protecting group, which acts as a Lewis base. Furthermore the extremely 
high regioselectivity observed in this step is also due to the presence of a bromo atom, 
which increases the acidity of that specific position by an inductive (ortho) effect (Sanz et 
al., 2005). 
The organolithium agent (lithium diisopropylamide, LDA) was created in situ at 0 °C 
using nBuLi and (iPr)2NH in anhydrous THF. The orhto-lithiation reaction was conducted 
at -78 °C because otherwise, upon warming, the resulting organolithium species undergoes 
a rearrangement to benzylic amides (the Snieckus-Fries rearrangement) via migration of 
the carbonyl carbon from oxygen to carbon.  
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Scheme 5. The regioselective ortho-lithiation. 
 
 
The ortho-lithiation is followed by a quenching with exachloroethane to insert the 
chlorine atom in the aromatic ring. Exachloroethane is an anhydrous and pure source of 
chlorine atom and, in the presence of Ar-Li, it releases a chlorine atom to replace the 
lithium by a disproportionation reaction, which produces tetrachloroethylene, as showed in 
Scheme 6. Tetrachloroethylene is then easily removed from the reaction mixture during 
solvent evaporation.  
 
 
 
 
Scheme 6. Quenching with exachloroethane. 
 
 
During my thesis work, the problem I met was the very low yield of this reaction, 
probably due to the fact that it was difficult to maintain the low temperature of -78 °C for 
all the time of the reaction, although I was able to obtain a sufficient amount of chlorinated 
product to complete the whole series of final products that I planned to synthesize. 
The next step (c in Scheme 3) is the alkaline hydrolysis of the carbamate group to 
deprotect the phenolic hydroxyl (Sanz et al., 2005). This reaction was conducted in EtOH 
and required NaOH as the base (Scheme 7). 
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Scheme 7. Hydrolysis of the carbamamoyl group. 
 
 
The carbammic acid is a good leaving group so its elimination is quite easy; once 
obtained intermediate 27b, the reaction was quenched with an aqueous solution of HCl to 
protonate the oxygen atom and to obtain the phenolic compound 28. 
Compound 28 was acetylated using NaOH as the deprotonating base and acetyl 
chloride as the acetyl group donor (Minutolo et al., 2009). In this reaction tetrabutyl-
ammonium-hydrogen-sulfate was used as the phase-transfer catalytic agent (Scheme 8). 
 
 
Scheme 8. Mechanism of the acetylation. 
 
 
After the deprotonation step, compound 28a acts as the nucleophile and attaches the 
carbonyl carbon of acetyl chloride, with the release of the chloride ion as leaving group. 
The final step of the preparation of key intermediate 22 was the transposition of the 
acetyl group by a Fries rearrangement catalyzed by a Lewis acid such as AlCl3 (Minutolo 
et al., 2009). This reaction is ortho and para selective and one of the preferential 
production of one of the  two regioisomers can be favoured by changing the reaction 
conditions, such as temperature and solvent. In this thesis the ortho selectivity was 
required, thus the reaction was conducted at high temperatures (130 °C; Scheme 9). 
Alternatively, if a para selectivity is desired, the reaction should be conducted at RT. 
27                                                            27a                                                                    27b                                           28 
28                                                 28a                                                         28b                                                             29 
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Scheme 9. Mechanism of the Fries rearrangement. 
 
 
In the first step aluminium trichloride AlCl3 co-ordinates to the carbonyl oxygen 
atom of the acyl group. This oxygen atom is more electron-rich than the phenolic oxygen 
atom and is the preferred Lewis base. This interaction polarizes the bond between the acyl 
residue and the phenolic oxygen atom and the aluminium chloride group rearranges to the 
phenolic oxygen atom. This generates a free acylium carbocation, which reacts in a 
classical electrophilic aromatic substitution with the aromatic ring. The abstracted proton is 
released as hydrochloric acid, where the chlorine is derived from aluminium chloride. 
In this way we have obtained compound 22, which is the starting material for the  
following reactions. The cross-coupling reaction was conducted under the Suzuki 
conditions, namely, in situ formation of Pd(PPh3)4 by reaction of palladium acetate with a 
5-fold excess of triphenylphosphine with an aqueous base and conventional heating at 100 
°C overnight (Minutolo et al., 2009); the catalytic cycle is reported in Scheme 10. 
29                                                    29a                                                29b                                                       22 
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Scheme 10. Catalysis cycle of the cross-coupling reaction. 
 
Step (a) of the cycle corresponds to the in situ reduction of PdII to generate the Pd(0) –
catalyst. This in situ reduction was preferred because of the high price of Pd(0)-complexes 
and due to its high instability. The Pd(0)–catalyst promotes an oxidative addition (b) to 
compound 22 to afford compound 22a. The complex aryl-Pd(II) acts as the electrophile to 
the aryl-boronate 22b, to do a transmetallation (d). An aqueous base (c) is required for this 
step because boronic acids are very stable compounds. The base makes the C-B bond of 
the boronic acid more labile: negatively charged B--species readily undergo 
transmetallation. Compound 22c undergoes a reductive elimination (e), Pd(0) is regenerated 
and the biaryl compound is eventually obtained. This way, the chemoselectivity 
replacement of the bromine atom only is guaranteed, whereas the chlorine atom is 
unreactive under these conditions. 
During my thesis work eight different boronic acids were used in the cross-coupling 
reaction to obtain different corresponding biarylic scaffolds. This reaction has always 
proceeded with good yields in all cases, with the exception of the 4-(cyano)-phenyl-
boronic acid and the 3-(cyano)-phenyl-boronic acid. In these two cases, in fact, the reaction 
22 
22a 
22b 
22c 
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gave unsatisfactory results under the classical Suzuki conditions, probably because the CN 
group is subjected to an undesired hydrolysis due to the presence of water in the reaction 
mixture. In the case of the reaction with the 4-(cyano)-phenyl boronic acid, the reaction has 
been performed with the previously used conditions, but the yield was very low (28%). To 
solve this problem, the reaction conditions were changed (Scheme 11): instead of using an 
aqueous solution of Na2CO3 as the base, we used solid anhydrous K2CO3, a non-aqueous 
base, to avoid the presence of water and, as consequence, the undesired hydrolysis of the 
cyano group. Moreover EtOH was not used in these conditions and the boronic acid was 
increased from 1.3 to 2 equivalents (Table 3) (Shieh & Carlson, 1992). This led to the 
efficient cross-coupling of the two cyano-substituted boronic acids too. 
 
 
Scheme 11. Modified conditions in the cross-coupling reaction with the 3-
(cyano)-phenyl boronic acid and 4-(cyano)-phenyl boronic acid. 
 
 
Table 3. Conditions used for compounds 24 a-d, g-h and 
optimized conditions for compound 24 e-f. 
 
Conditions of the 
reaction 
Catalyst Base Solvent Eq of 
boronic 
acid 
Time and 
temperature 
Yield 
Suzuki conditions used 
for compounds 24 a-d, 
g-h 
Pd(OAc)2 
PPh3 
Na2CO3(aq) 
2M 
Toluene 
EtOH 
1.3 24 h 
100 °C 
59-94% 
Optimized conditions for 
compounds 24 e-f 
Pd(OAc)2 
PPh3 
K2CO3 Toluene 2.0 24 h 
100 °C 
55-69% 
+ 
K2CO3 
Pd(OAc)2 
P(Ph)3 
Toluene 
100 °C, 16h 
B 
B 
A 
A 
B 
A 
22 23 e-f 24 e-f 
e: p-CN                       
f: m-CN 
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The last step of this synthetic pathway (Scheme 2) consists in the condensation of  
the ketone group with hydroxylamine hydrochloride to afford the final products. The 
mechanism of this reaction is a condensation reaction of the nucleophilic hydroxylamine 
and the carboxyl group. (Scheme 12). 
 
 
Scheme 12. Mechanism of the condensation of the hydroxylamine and the salicylketone. 
 
Also in this case I had to optimize the reaction conditions starting from what was 
reported in literature (Minutolo et al., 2009): in fact my reaction generally required a 
longer reaction times (48 h instead of 1 h) and a large excess of hydroxylamine (3 
equivalent instead of 2). 
The final products obtained with this reaction are exclusively of E-configuration, 
whereas the Z-configuration is not obtained because the first one is stabilized by the 
phenolic hydroxyl, which forms a pseudo cycle through an intramolecular hydrogen bond 
with the nitrogen atom of the oxime (Fig. 25). This is confirmed by the chemical shifts of 
the methyl protons, which is in the range of 2.35-2.41 ppm (Ngwerumw & Camp, 2010); on 
the contrary, the corresponding chemical shifts range in Z-ketoxime are generally lower 
then 2.0 ppm. Moreover, the most significant data, is the chemical shift obtained for the 
methyl carbon of the compound 19, which is 10.05 ppm and it corresponds to the values 
observed for the E isomer of aromatic ketoximes reported in literature, unlike the 
corresponding chemical shift for the Z isomer which is in the range of 21.0-21.4 ppm. 
(Moehrle et al., 1987). 
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Fig. 25. Comparison between E- and Z-ketoxime. 
 
 
The COSY and HSQC spectra reported in Fig. 26 and Fig. 27, respectively,  are relative to 
representative compound 19 and are herein reported as a further evidence of a proper 
structural characterization.  In the COSY spectrum (Fig. 26) the coupling of the aromatic 
protons in the range between 7.00 and 7.87 ppm is consistent with the structure of the 
compounds. Moreover  the HSQC spectrum (Fig. 27) unequivocally associates the 
diagnostic methyl group, which is fundamental for the proper assignment of the E- 
configurations of these ketoximes, to the proton signal at 2.43 ppm and the carbon peak at 
10.05 ppm. Finally the associations of all the aromatic carbons (120.00-140.00 ppm) with 
their proton signals (7.00-7-87 ppm), are displayed as expected. 
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Fig. 26. COSY spectrum of compound 19. 
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Fig. 27. HSQC spectrum of compound 19. 
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4. Summary and conclusions  
 
The family of glucose transporters (GLUTs) comprises 12 isoforms of trans-
membrane channel proteins, which allow the entrance of D-glucose into the cells. These 
isoforms possess different affinities for glucose and other hexoses and each isoform has a 
tissue-specific distribution. Isoform GLUT-1 was the object of this thesis, since it was 
found to be overexpressed in most carcinoma cell-type. The over-expression of this protein 
in the tumor cell membranes allows this type of cells to accumulate and use a large amount 
of D-glucose and, consequently, to produce enough energy for their rapid growth and 
survival. In fact, tumor cells predominantly produce energy by a high rate of glycolysis, 
followed by lactic acid fermentation in the cytosol, rather than by a comparatively low rate 
of glycolysis followed by oxidation of pyruvate in mitochondria, such as that occurring in 
most normal cells. This metabolic switch is known as the Warburg Effect. Therefore, 
GLUT-1 inhibition may represent a very attractive way to attack cancer by blocking its 
main nutrient uptake, thus leading to a decrease in glycolytic flux and to cell death by 
starvation. 
So far, several molecules have been reported to be able to block glucose uptake. 
Most of them are natural molecules such as flavonoids, flavones, chalcones, but there are 
also examples of synthetic molecules, such as tamoxifen, fulvestrant, 17β-estradiol. The 
interesting thing is that a large portion of these molecules are also active on estrogen 
receptor beta (ERβ). Based on this concept, some salycilaldoxime and salicylketoxime 
derivatives, that had been previously designed and synthesized as potential ERβ-ligands in 
the research group where I have carried out my thesis project, were also tested in cellular 
assays on GLUT-1, and some of them displayed good inhibitory activities on glucose 
uptake.  
The recent crystallization (resolution 2.9 Å) of the xylose transporter of E. Coli, 
XyLE, coordinated with D-glucose provided a valid starting point for a more accurate 
analysis of human GLUT-1 and to study the putative interaction modes of the most active 
salicylketoxime molecules and flavonoids. This transporter is formed by 492 amino acids; 
there are 12 transmembranes and 4 intracellular helices and both the N-terminus and C-
terminus are located in the intracellular part of the protein. The aqueous channel seems to 
be divided into two parts by two residues that form a gate in the middle of the channel: 
Trp388 and His154. 
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Considering the pharmacophoric features required to have a good inhibitory activity 
on GLUT-1, some substitutions were made in the positions R1 and R2 of the general 
structure indicated below (Fig. 26). 
 
 
 
Fig. 26. General structure of the synthesized compounds. 
 
 
The project of my thesis was dedicated to study the introduction of various 
substituents (R1 and R2) in the phenyl ring. The starting material for the synthesis of these 
compounds was the commercial 3-bromophenol, which was carbamoylated on the 
hydroxyl group. Then, an ortho-lithiation, followed by a quenching with hexachloroethane, 
produced the regioselective insertion of a chlorine atom in position 2 of the aromatic ring. 
The corresponding 2-chloro-3-bromo-carbamoylphenol was hydrolysed under basic 
conditions, to deprotect the phenolic hydroxyl and to obtain 3-bromo-2-chloro-phenol. 
This molecule was acetylated and then the acetyl group was transposed by a Fries 
rearrangement reaction to afford 3-bromo-2-chloro-6-acetylphenol. The latter was the key-
intermediate for the structural variations of my compounds, which was in fact submitted to 
various cross-coupling reactions under Suzuki conditions using different boronic-acids to 
obtain variously substituted ketone intermediates. The ketone group was finally 
transformed into the desired ketoxime. 
During this thesis work eight new compounds were obtained. The final products are 
currently being evaluated for glucose uptake inhibition and antiproliferative activity 
against cancer cells. 
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5. Experimental procedures 
 
 
Materials and methods 
 
 
Structure of synthesized compound was verified by 1H NMR and 13C NMR analysis. 
NMR spectra were obtained with a Varian Gemini 200 spectrometer working at 200MHz 
or a Bruker Avance III HD operating at 400MHz and relative to the solvent signal. 
Chemical shift (δ) are reported in parts per million (ppm) and coupling constants (J) in Hz. 
The following abbreviations were used to explain the multiplicities: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, dt = double triplet, dd = double doublet. 
Evaporation was performed under vacuum conditions in rotating evaporator. All reactions 
was monitored by thin-layer chromatography (TLC) using Merck aluminium silica gel (60 
F254) sheets that were visualized under a UV lamp (254 nm). Silica gel flash 
chromatography was performed using silica gel 60 (0.040-0.063 mm; Merck). Anhydrous 
sodium sulfate was always used ad the drying agent. Yields refer to isolated and purified 
products. 
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Compound 26 
 
 
 
 
 
 
 
 
 
 
 
 
3-Bromophenyl N,N-diethylcarbamate 
 
 
To a well-stirred suspension of a mineral oil dispersion of NaH 60% (1.39 g, 34.7 
mmol) in dry THF (17 mL) in a flame-dried two-necked round bottomed flask, a solution 
of 3-bromophenol (25) (3.00 g, 17.3 mmol) was dropwise added at room temperature 
under nitrogen atmosphere. After 3h, N,N-diethylcarbamoylchloride (4.4 mL, 35 mmol) in 
dry THF (6 mL) was added. Stirring was continued for 12 h. The mixture was neutralized 
with HCl 1N and the organic phase was extracted AcOEt. The combined organic phases 
was dried and evaporated under reduced pressure. The crude product was purified by 
column chromatography (n-Hexane/AcOEt 95:5) on silica gel to afford compound 26 as a 
yellow oil and the yield of this reaction was > 99%. 
 
 
1H NMR (CDCl3) δ (ppm): 
1.22 (q, 6H, J = 7.1 Hz); 3.30-3.50 (m, 4H); 7.08 (dt, 1H, J = 8.1; 1.6 Hz); 7.20 (d, 
1H, J = 8.4 Hz); 7.28-7.36 (m, 2H) 
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Compound 27 
 
 
 
 
 
 
 
 
 
 
 
 
2-Chloro-3-bromophenyl N,N-diethylcarbamate 
 
 
Under nitrogen atmosphere, 5.1 mL of nBuLi 1,60 M was added to a solution of 
(iPr)2NH (1.1 mL, 8.1 mmol) in dry THF (22 mL) at 0 °C and the mixture was stirred for 
30’ in a flame-dried two-necked round bottomed flask. Than, the LDA solution was cooled 
at -78 °C using a dry ice bath, and compound 26 (2.00 g, 7.35 mmol) was added. The 
resulting solution was stirred for 30' at -78 °C and then, C2Cl6 (2.09 g, 8.82 mmol) was 
added. After 30’ at low temperature, the reaction mixture was allowed to warm to room 
temperature and was quenched with H2O. THF was evaporated under reduced pressure and 
the aqueous phase was extracted with AcOEt. The combined organic phases were dried 
over anhydrous Na2SO4 and evaporated under reduced pressure. The crude product was 
purified by column chromatography on silica gel (n-Hexane/AcOEt 9:1), to afford 
compound 27. The yield of this reaction was 30%. 
 
 
1H NMR (CDCl3) δ (ppm):  
1.25 (dt, 6H, J = 16.1, 7.1 Hz); 3.44 (dq, 4H, J = 18.4, 7.1 Hz); 7.08-7.23 (m, 2H); 
7.48 (dd, 1H, J = 7.3, 2.2 Hz) 
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Compound 28 
 
 
 
 
 
 
 
 
 
 
 
3-Bromo-2-chlorophenol 
 
 
To a solution of compound 27 (1.34 g, 4.36 mmol), in EtOH (44 mL), a large excess 
of NaOH (1.74 g, 43.6 mmol) was added under nitrogen conditions in a flame-dried 
double-necked round flask. The mixture was refluxed overnight at 70. After cooling to 
room temperature most of EtOH was evaporated under reduced pressure and the residue 
was diluted with Et2O. The excess of NaOH was neutralized at 0 °C with HCl 1N. The 
aqueous solution was extracted with Et2O and the combined organic phases was washed 
with brine, dried and evaporated under reduced pressure. The crude product was purified 
by column chromatography on silica gel (n-Hexane/AcOEt 85:15) to afford compound 28 
pure. Compound 28 was obtained as a yellow oil with a yield > 99%. 
 
 
1H NMR (CDCl3) δ (ppm):  
5.75 (s, 1H); 6.97 (dd, 1H, J = 8.1, 1.9 Hz); 7.06 (t, 1H, J = 7.9 Hz); 7.20 (dd, 1H, J 
=7.6, 1.9 Hz) 
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Compound 29 
 
 
 
 
 
 
 
 
 
 
 
3-Bromo-2-chlorophenyl acetate 
 
 
A solution of compound 28 (1.20 g 5.80 mmol) in dioxane (8.7 mL), was treated 
under inert atmosphere with solid NaOH (0.56 g, 14 mmol) and tetrabutyl ammonium 
hydrogen sulfate (6.31 g, 0.02 mmol) and the mixture was stirred at room temperature for 
30'. A solution of acetylchloride (0.47 mL, 6.7 mmol) in dioxane (5.3 mL) was added with 
a syringe through a silicon septum. Once the addiction was completed, stirring was 
continued for 1h. The reaction mixture was then poured into ice and extracted with AcOEt. 
The organic phase was dried and evaporated under reduced pressure. The crude product 
was purified by a column chromatography in silica gel (n-Hexane/AcOEt 9:1) to afford 
compound 29 as a yellow oil with a yield of 66%. 
 
 
1H NMR (CDCl3) δ (ppm):  
2.36 (s, 3H); 7.07-7.21 (m, 2H); 7.53 (dd, 1H, J = 7.4, 1.7 Hz) 
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Compound 22 
 
 
 
 
 
 
 
 
 
 
 
 
1-(4-Bromo-3-chloro-2-hydroxyphenyl)ethanone 
 
 
Compound 29 (200 mg, 0.80 mmol) was treated neat with AlCl3 (138.7 mg, 1.04 
mmol) and the mixture was heated at 130 °C in a sealed vial for 3-4 h. After cooling at RT, 
the crude mixture was treated with aqueous HCl 1N and extracted with AcOEt. The 
organic phase was dried and concentrated. The crude product was purified with 
chromatography column in silica gel (n-Hexane/Diethylether 9:1), to afford compound 22 
as white crystals with a yield of 70%. 
 
 
1H NMR (CDCl3) δ (ppm):  
2.65 (s, 3H); 7.22 (d, 1H, J = 8.6 Hz); 7.53 (d, 1H, J = 8.6 Hz); 13.13 (s, 1H) 
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Compound 24a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1-(2-Chloro-3-hydroxy-4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)ethanone 
 
 
A solution of Pd(OAc)2 (0.62 mg, 9.2 µmol) and PPh3 (12.1 mg, 0.05 mmol) in 
EtOH (0.4 mL) and toluene (0.4 mL) was stirred, in a sealed vial, at room temperature 
under nitrogen for 10’. Then, compound 22 (100 mg, 0.40 mmol), Na2CO3 2M (0.4 mL) 
and 4-(trifluoromethoxy)phenyl-boronic acid (107.1 mg, 0.52 mmol) were sequentially 
added. The resulting mixture was heated at 100 °C in a sealed vial under nitrogen 
overnight. The solution was treated with H2O and HCl 1N and the aqueous phase was 
extracted with AcOEt. The crude product was purified with chromatography column in 
silica gel (n-Hexane/AcOEt 95:5) to afford compound 24a as a yellow oil. The yield was 
79%. 
 
 
1H NMR (CDCl3) δ (ppm):  
2.70 (s, 3H); 6.91 (d, 1H, J = 8.2 Hz); 7.26-7.36 (m, 2H); 7.48 (AA’XX’, 2H, JAX = 
8.6 Hz, JAA’/XX’ = 2.1 Hz); 7.72 (d, 1H, J = 8.2 Hz) 
 
 
 50 
Compound 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(E)-1-(2-chloro-3-hydroxy-4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)ethanone oxime 
 
 
A solution of compound 24a (70.0 mg, 0.21 mmol) in EtOH (4.0 mL) under N2, was 
treated with a solution of NH2OH HCl (29.19 mg, 0.42 mmol) in H2O (0.9 mL) and the 
mixture was refluxed to 50 °C for 48 h. After being cooled to room temperature, part of the 
solvent was removed under N2 and extracted with AcOEt. The crude product was dried, 
concentrated under reduce pressure and purified with a silica gel column (eluent n-
Hexane/AcOEt 9:1) to afford compound 14 as a yellow solid. The yield of this reaction 
was 90%. 
 
 
1H NMR (Acetone-d6) δ (ppm):  
2.43 (s, 3H); 6.97 (d, 1H, J = 8.2 Hz); 7.40-7.48 (m, 2H); 7.56-7.64 (m, 3H); 12.40 
(bs, 1H) 
 
1H NMR (CDCl3) δ (ppm):  
2.40 (s, 3H); 6.89 (d, 1H, J = 8.2 Hz); 7.23-7.32 (m, 2H); 7.41 (d, 1H, J = 8.4 Hz); 
7.48 (AA’XX’, 2H, JAX  = 8.6 Hz, JAA’/XX’ = 2.1 Hz) 
 51 
Compound 24b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1-(2-Chloro-3-hydroxy-3'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)ethanone 
 
 
A solution of Pd(OAc)2 (0.50 mg, 7.4 µmol) and PPh3 (9.7 mg, 0.04 mmol) in EtOH 
(0.3 mL) and toluene (0.3 mL) was stirred, in a sealed vial, at room temperature under 
nitrogen for 10’. Then, compound 22 (80.0  mg, 0.32 mmol), Na2CO3 2M (0.3 mL) and 3-
(trifluoromethoxy)phenyl-boronic acid (86.5 mg, 0.42 mmol) were sequentially added. The 
resulting mixture was heated at 100 °C in a sealed vial under nitrogen overnight. The 
solution was treated with H2O and HCl 1N and the aqueous phase was extracted with 
AcOEt. The crude product was purified with chromatography column in silica gel (n-
Hexane/AcOEt 95:5) to afford compound 24b as a yellow oil. The yield was 78%. 
 
 
1H NMR (CDCl3) δ (ppm):  
2.70 (s, 3H); 6.92 (d, 1H, J = 8.2 Hz); 7.29-7.54 (m, 4H); 7.73 (d, 1H, J = 8.2 Hz) 
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Compound 15 
 
 
 
 
 
 
 
 
 
(E)-1-(2-chloro-3-hydroxy-4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)ethanone oxime 
 
 
A solution of compound 24b (50.0 mg, 0.15 mmol) in EtOH (2.9 mL) under N2, was 
treated with a solution of NH2OH HCl (20.8 mg, 0.30 mmol) in H2O (0.7 mL) and the 
mixture was refluxed to 50 °C for 48 h. After being cooled to room temperature, part of the 
solvent was removed under N2 and extracted with AcOEt. The crude product was dried, 
concentrated under reduce pressure and purified with a silica gel column (eluent n-
Hexane/AcOEt 9:1) to afford compound 15 as a white solid. The yield of this reaction was 
80%. 
 
 
1H NMR (Acetone-d6) δ (ppm):  
2.42 (s, 3H); 6.98 (d, 1H, J = 8.2 Hz); 7.34-7.53 (m, 3H); 7.55-7.67 (m, 2H); 11.02 
(s, 1H); 12.50 (s, 1H) 
 
1H NMR (CDCl3) δ (ppm):  
2.42 (s, 3H); 6.91 (d, 1H, J = 8.2 Hz); 7.31-7.53 (m, 5H) 
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Compound 24c 
 
 
 
 
 
 
 
 
 
1-(2-Chloro-3-hydroxy-4'-methoxy-[1,1'-biphenyl]-4-yl)ethanone 
 
 
A solution of Pd(OAc)2 (0.50 mg, 7.4 µmol) and PPh3 (9.70 mg, 0.04 mmol) in 
EtOH (0.3 mL) and toluene (0.3 mL) was stirred, in a sealed vial, at room temperature 
under nitrogen for 10’. Then, compound 22 (80.0 mg, 0.32 mmol), Na2CO3 2M (0.3 mL) 
and 4-(methoxy)phenyl-boronic acid (63.8 mg, 0.42 mmol) were sequentially added. The 
resulting mixture was heated at 100 °C in a sealed vial under nitrogen overnight. The 
solution was treated with H2O and HCl 1N and the aqueous phase was extracted with 
AcOEt. The crude product was purified with chromatography column in silica gel (n-
Hexane/AcOEt 9:1) to afford compound 24c as a yellow solid. The yield was 69%. 
 
 
1H NMR (CDCl3) δ (ppm):  
2.68 (s, 3H); 3.87 (s, 3H); 6.92 (d, 1H, J = 8.2 Hz); 6.99 (AA’XX’, 2H, JAX  = 9.0 
Hz, JAA’XX’= 2.0); 7.42 (AA’XX’, 2H, JAX  = 8.8 Hz, JAA’/XX’ = 2.2 Hz); 7.69 (d, 1H, J = 8.2 
Hz) 
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Compound 16 
 
 
 
 
 
 
 
 
 
(E)-1-(2-chloro-3-hydroxy-4'-methoxy-[1,1'-biphenyl]-4-yl)ethanone oxime 
 
 
A solution of compound 24c (40.0 mg, 0.14 mmol) in EtOH (2.7 mL) under N2, was 
treated with a solution of NH2OH HCl (19.5 mg, 0.28 mmol) in H2O (0.6 mL) and the 
mixture was refluxed to 50 °C for 48 h. After being cooled to room temperature, part of the 
solvent was removed under N2 and extracted with AcOEt. The crude product was dried, 
concentrated under reduce pressure and purified with a silica gel column (eluent n-
Hexane/AcOEt 9:1) to afford compound 16 as a yellow solid. The yield of this reaction 
was 64%. 
 
 
1H NMR (Acetone-d6) δ (ppm):  
2.40 (s, 3H); 3.85 (s, 3H); 6.91 (d, 1H, J = 8.3 Hz); 7.01 (AA’XX’, 2H, JAX  = 6.7 
Hz, JAA’XX’ = 2.2 Hz); 7.40 ( AA’XX’, 2H, JAX  = 6.7 Hz, JAA’XX’ = 2.2 Hz); 7.55 (d, 1H, J 
= 8.3 Hz); 10.91 (s, 1H); 12.40 (s, 1H) 
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Compound 24d 
 
 
 
 
 
 
 
 
 
1-(2-Chloro-3-hydroxy-3'-methoxy-[1,1'-biphenyl]-4-yl)ethanone  
 
 
A solution of Pd(OAc)2 (0.50 mg, 7.4 µmol) and PPh3 (9.7 mg, 0.04 mmol) in EtOH 
(0.3 mL) and toluene (0.3 mL) was stirred, in a sealed vial, at room temperature under 
nitrogen for 10’. Then, compound 22 (80.0 mg, 0.32 mmol), Na2CO3 2M (0.3 mL) and 3-
(methoxy)phenyl-boronic acid (63.8 mg, 0.42 mmol) were sequentially added. The 
resulting mixture was heated at 100 °C in a sealed vial under nitrogen overnight. The 
solution was treated with H2O and HCl 1N and the aqueous phase was extracted with 
AcOEt. The crude product was purified with chromatography column in silica gel (n-
Hexane/AcOEt 95:5) to afford compound 24d as a white solid. The yield was 59%. 
 
 
1H NMR (CDCl3) δ (ppm):  
2.60 (s, 3H); 3.85 (s, 3H); 6.90-7.06 (m, 4H); 7.38 (t, 1H, J = 7.4 Hz); 7.71 (d, 1H, J 
= 8.4 Hz) 
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Compound 17 
 
 
 
 
 
 
 
 
 
(E)-1-(2-Chloro-3-hydroxy-3'-methoxy-[1,1'-biphenyl]-4-yl)ethanone oxime 
 
 
A solution of compound 24d (50.0 mg, 0.18 mmol) in EtOH (3.4 mL) under N2, was 
treated with a solution of NH2OH HCl (25.0 mg, 0.36 mmol) in H2O (0.8 mL) and the 
mixture was refluxed to 50 °C for 48 h. After being cooled to room temperature, part of the 
solvent was removed under N2 and extracted with AcOEt. The crude product was dried, 
concentrated under reduce pressure and purified with a silica gel column (eluent n-
Hexane/AcOEt 9:1) to afford compound 17 as a white-yellow solid. The yield of this 
reaction was 67%. 
 
 
1H NMR (Acetone-d6) δ (ppm):  
2.41 (s, 3H); 3.84 (s, 3H); 6.90-7.40 (m, 4H); 7.31-7.40 (m, 1H); 7.58 (d, 1H, J = 8.4 
Hz); 10.96 (s, 1H); 12.43 (s, 1H) 
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Compound 24e 
 
 
 
 
 
 
 
 
 
4'-Acetyl-2'-chloro-3'-hydroxy-[1,1'-biphenyl]-4-carbonitrile 
 
 
A solution of Pd(OAc)2 (4.0 mg, 6.0 µmol) and PPh3 (8.1 mg, 0.03 mmol) in toluene 
(1.9 mL) was stirred, in a sealed vial, at room temperature under nitrogen for 10’. Then, 
compound 22 (50.0 mg, 0.20 mmol), K2CO3 (41.5 mg, 0.30 mmol) and 4-(cyano)phenyl-
boronic acid (58.8 mg, 0.40 mmol) were sequentially added. The resulting mixture was 
heated at 100 °C in a sealed vial under nitrogen overnight. The solution was treated with 
H2O and HCl 1N and the aqueous phase was extracted with AcOEt. The crude product was 
purified with chromatography column in silica gel (n-Hexane/AcOEt 8:2) to afford 
compound 24e as a light yellow solid. The yield was 55%. 
 
 
1H NMR (CDCl3) δ (ppm):  
2.71 (s, 3H); 6.89 (d, 1H, J = 8.2 Hz); 7.52-7.62 (m, 2H); 7.72-7.80 (m, 3H) 
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Compound 18 
 
 
 
 
 
 
 
 
 
(E)-2'-Chloro-3'-hydroxy-4'-(1-(hydroxyimino)ethyl)-[1,1'-biphenyl]-4-carbonitrile 
 
 
A solution of compound 24e (39.1 mg, 0.14 mmol) in EtOH (2.7 mL) under N2, was 
treated with a solution of NH2OH HCl (19.5 mg, 0.28 mmol) in H2O (0.6 mL) and the 
mixture was refluxed to 50 °C for 96 h. After being cooled to room temperature, part of the 
solvent was removed under N2 and extracted with AcOEt. The crude product was dried, 
concentrated under reduce pressure and purified with a silica gel column (eluent n-
Hexane/AcOEt 8:2) to afford compound 18 as a white solid. The yield of this reaction was 
71%. 
 
 
1H NMR (Acetone-d6) δ (ppm):  
2.43 (s, 3H); 6.98 (d, 1H, J = 8.2 Hz); 7.64 (d, 1H, J = 8.3 Hz); 7.68 (AA’XX’, 2H, 
JAX = 8.1 Hz, JAA’XX’ = 1.4 Hz); 7.89 (AA’XX’, 2H, JAX  = 8.6 Hz, JAA’XX’ = 1.8 Hz ); 11.04 
(s, 1H); 12.52 (s, 1H). 
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Compound 24f 
 
 
 
 
 
 
 
 
 
4'-Acetyl-2'-chloro-3'-hydroxy-[1,1'-biphenyl]-3-carbonitrile 
 
 
A solution of Pd(OAc)2 (6.5 mg, 9.6 µmol) and PPh3 (12.9 mg, 0.05 mmol) in 
toluene (3.1 mL) was stirred, in a sealed vial, at room temperature under nitrogen for 10’. 
Then, compound 22 (80.0 mg, 0.32 mmol), K2CO3 (66.3 mg, 0.48 mmol) and 3-
(cyano)phenyl-boronic acid (94.04 mg, 0.64 mmol) were sequentially added. The resulting 
mixture was heated at 100 °C in a sealed vial under nitrogen overnight. The solution was 
treated with H2O and HCl 1N and the aqueous phase was extracted with AcOEt. The crude 
product was purified with chromatography column in silica gel (n-Hexane/AcOEt 8:2) to 
afford compound 24f as a light yellow solid. The yield was 69%. 
 
 
1H NMR (CDCl3) δ (ppm):  
2.71 (s, 3H); 6.89 (d, 1H, J = 8.2 Hz); 7.58 (t, 1H, J = 7.7 Hz); 7.68-7.74 (m, 4H); 
13.09 (s, 1H) 
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Compound 19 
 
 
 
 
 
 
 
 
 
(E)-2'-Chloro-3'-hydroxy-4'-(1-(hydroxyimino)ethyl)-[1,1'-biphenyl]-3-carbonitrile 
 
 
A solution of compound 24f (40.0 mg, 0.15 mmol) in EtOH (2.9 mL) under N2, was 
treated with a solution of NH2OH HCl (20.8 mg, 0.30 mmol) in H2O (0.6 mL) and the 
mixture was refluxed to 50 °C for 48 h. After being cooled to room temperature, part of the 
solvent was removed under N2 and extracted with AcOEt. The crude product was dried, 
concentrated under reduce pressure and purified with a silica gel column (eluent n-
Hexane/AcOEt 9:1) to afford compound 19 as a yellow solid. The yield of this reaction 
was 73%. 
 
 
1H NMR (Acetone-d6) δ (ppm):  
2.43 (s, 3H); 7.00 (d, 1H, J = 8.2 Hz); 7.64 (d, 1H, J = 8.2 Hz); 7.70 (t, 1H, J = 7.7 
Hz); 7.79-7.87 (m, 3H) 
 
1H NMR (CDCl3) δ (ppm):  
2.42 (s, 3H); 6.88 (d, 1H, J = 8.2 Hz); 7.44 (d, 1H, J = 8.3 Hz); 7.56 (t, 1H, J = 7.8 
Hz); 7.68-7.73 (m, 2H); 7.76 (t, 1H, J = 1.4 Hz) 
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Compound 24g 
 
 
 
 
 
 
 
 
 
1-(2,3'-Dichloro-3-hydroxy-4'-methoxy-[1,1'-biphenyl]-4-yl)ethanone 
 
 
A solution of Pd(OAc)2 (0.50 g, 7.4 µmol) and PPh3 (9.7 mg, 0.04 mmol) in EtOH 
(0.3 mL) and toluene (0.3 mL) was stirred, in a sealed vial, at room temperature under 
nitrogen for 10’. Then, compound 22 (80.0 mg, 0.32 mmol), Na2CO3 2M (0.3 mL) and 3-
(chloro)-4-(methoxy)phenyl-boronic acid (78.3 mg, 0.42 mmol) were sequentially added. 
The resulting mixture was heated at 100 °C in a sealed vial under nitrogen overnight. The 
solution was treated with H2O and HCl 1N and the aqueous phase was extracted with 
AcOEt. The crude product was purified with chromatography column in silica gel (n-
Hexane/AcOEt 9:1) to afford compound 24g as a white solid. The yield was 88%. 
 
 
1H NMR (CDCl3) δ (ppm):  
2.69 (s, 3H); 3.97 (s, 3H); 6.90 (d, 1H, J = 8.2 Hz); 7.01 (d, 1H, J = 8.6 Hz); 7.37 
(dd, 1H, J = 8.4, 2.2 Hz); 7.49 (d, 1H, J = 2.2 Hz); 7.70 (d, 1H, J = 8.4 Hz) 
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Compound 20 
 
 
 
 
 
 
 
 
 
(E)-1-(2,3'-dichloro-3-hydroxy-4'-methoxy-[1,1'-biphenyl]-4-yl)ethanone oxime 
 
 
A solution of compound 24g (50.0 mg, 0.19 mmol) in EtOH (3.6 mL) under N2, was 
treated with a solution of NH2OH HCl (26.4 mg, 0.38 mmol) in H2O (0.8 mL) and the 
mixture was refluxed to 50 °C for 48 h. After being cooled to room temperature, part of the 
solvent was removed under N2 and extracted with AcOEt. The crude product was dried, 
concentrated under reduce pressure and purified with a silica gel column (eluent n-
Hexane/AcOEt 9:1) to afford compound 20 as a white solid. The yield of this reaction was 
47%. 
 
 
1H NMR (Acetone-d6) δ (ppm): 
2.42 (s, 3H); 3.97 (s, 3H); 6.95 (d, 1H, J = 8.2 Hz); 7.21 (d, 1H, J = 8.5 Hz); 7.40 
(dd, 1H, J = 8.5, 2.2 Hz); 7.49 (d, 1H, J = 2.2 Hz); 7.58 (d, 1H, J = 8.3 Hz); 10,96 (s, 1H); 
12.45 (s, 1H). 
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Compound 24h 
 
 
 
 
 
 
 
1-(2-Chloro-3-hydroxy-4'-methoxy-3'-methyl-[1,1'-biphenyl]-4-yl)ethanone 
 
 
A solution of Pd(OAc)2 (0.50 mg, 7.4 µmol) and PPh3 (9.7 mg, 0.04 mmol) in EtOH 
(0.3 mL) and toluene (0.3 mL) was stirred, in a sealed vial, at room temperature under 
nitrogen for 10’. Then, compound 22 (80.0 mg, 0.32 mmol), Na2CO3 2M (0.3 mL) and 3-
(metyl)-4-(methoxy)phenyl-boronic acid (69.7 mg, 0.42 mmol) were sequentially added. 
The resulting mixture was heated at 100 °C in a sealed vial under nitrogen overnight. The 
solution was treated with H2O and HCl 1N and the aqueous phase was extracted with 
AcOEt. The crude product was purified with chromatography column in silica gel (n-
Hexane/AcOEt 95:5) to afford compound 24h as a yellow solid . The yield was 94%. 
 
 
1H NMR (CDCl3) δ (ppm):  
2.28 (s, 3H); 2.68 (s, 3H); 3.89 (s, 3H); 6.91 (d, 1H, J = 8.4 Hz); 6.92 (d, 1H, J = 8.3 
Hz); 7.24-7.25 (m, 1H); 7.32 (dd, 1H, J = 2.3, 0.4 Hz); 7.68 (d, 1H, J = 8.3 Hz); 13.10 (s, 
1H) 
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Compound 21 
 
 
 
 
 
 
 
 
(E)-1-(2-chloro-3-hydroxy-4'-methoxy-3'-methyl-[1,1'-biphenyl]-4-yl)ethanone oxime 
 
 
A solution of compound 24h (40.0 mg, 0.16 mmol) in EtOH (3.1 mL) under N2, was 
treated with a solution of NH2OH HCl (22.2 mg, 0.32 mmol) in H2O (0.7 mL) and the 
mixture was refluxed to 50 °C for 48 h. After being cooled to room temperature, part of the 
solvent was removed under N2 and extracted with AcOEt. The crude product was dried, 
concentrated under reduce pressure and purified with a silica gel column (eluent n-
Hexane/AcOEt 9:1 ) to afford compound 21 as a white solid . The yield of this reaction 
was  63%. 
 
 
1H NMR (Acetone-d6) δ (ppm): 
2.23 (s, 3H); 2.41 (s, 3H); 3.89 (s, 3H); 6.91 (d, 1H, J = 8.4 Hz); 6.89-7.01 (m, 1H); 
7.20-7.30 (m, 2H); 7.55 (d, 1H, J = 8.4 Hz); 10.93 (s, 1H); 12.40 (s, 1H) 
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